Gonadotropins
MASCULINIZATION
One patient had unmeasurable LH before the study start; 10 patients (8 TE and 2 TU) at 3 months, nine patients (6 TE and 3 TU) at 6 months, and no patient at 12 months had unmeasurable LH. The patient with unmeasurable LH levels at the study start and at 3 and 6 months had an LH level of 2.0 mIU/ml at 12 months and a testosterone level of 0.6 nmol/L at the start, 3.8 at 3 months, 4.3 at 6 months, and 6.8 at 12 months. He was treated with TE and had a TV of 2 ml bilaterally at the start and 10 ml at 12 months. The mean LH levels were similar in the two groups: 1.0 mIU/ml at the start and 2.6 after 12 months in the TU group, versus 1.0 mIU/ml at the start and 2.54 after 12 months in the TE group, with the lowest mean LH values seen at 3 months (i.e., 0.76 and 0.32 mIU/ml in the TU and TE groups, respectively). All patients had measurable FSH values at the start and after 3, 6, and 12 months. Gonadotropin data for the TU and TE groups are presented in Gonadotropin levels in patients in the Pubertal Replacement in Boys Study.LH, luteinizing hormone; FSH, follicle-stimulating hormone.The two patients in the TU group who did not reach the primary endpoint had LH values of 1.0 and 2.0 mIE/ml at the study start and of 3.0 and 3.8 mIU/ml at 12 months. Their FSH levels were 5.8 and 10.5 mIU/ml at the study start (the TU group mean was 2.4 mIU/ml) and 14 and 10.7 mIU/ml at 12 months (the TU group mean was 4.8 mIU/ml). The mean LH and FSH levels are shown in Mean gonadotropins (LH and FSH) in the Pubertal Replacement in Boys Study in the Testoviron DepotFor DHEAS and inhibin B, long-term safety, bone age, growth, testicular growth, and signs of masculinization, see 